复旦大学附属儿科医院《中国新生儿协作网 2023 年度报告》显示，我国胎龄小于 32 周的极早产儿存活率已达 90.2%，但严重并发症发生率仍高达 38.5%，远高于发达国家 20% 以下的水平。每年超 150 万早产儿中，胎龄 28 周以下的极早产儿面临着 20 万元以上的人均救治成本和长期神经发育障碍风险。这种临床困境催生了人造机器子宫技术的全球竞争，而美国 Vitara Biomedical 公司与中国苏州赛吉生物科技有限公司（SAGE-BIO）的技术，成为该领域最引人注目的发展脉络。

       Vitara Biomedical 公司的 EXTEND 系统已获得 FDA"突破性疗法" 认定，其核心技术通过充满电解质溶液的生物袋模拟子宫环境，将脐动静脉与外部循环系统连接实现生命支持。在 2019 年的里程碑实验中，该系统成功让妊娠 23-24 周的羔羊体外存活 28 天，期间羔羊肺部和大脑发育正常，死亡率降低 81%。这一突破使其计划于 2025 年启动首次人体临床试验，成为全球该领域的标杆。

       苏州赛吉生物于2021年启动相关项目并于2022年注册公司， 2023 年 6 月提交 "用于超早产胎儿体外维生系统" 发明专利（申请号：202310689273.XX）和 2024 年 5 月完成的原型机核心功能验证，成为亚洲首个在该领域实现全链条技术突破的企业。其 SAUO （Simulated Artificial Uterus One, 即第一代模拟机器子宫）系统不仅对标 Vitara 的技术标准，更针对中国早产儿生理特征进行创新优化，在专利布局、原型机进展和临床前数据等关键节点上，建立了显著的区域领先优势。

Vitara 的突破与赛吉的追赶

       Vitara 的 EXTEND 系统代表了当前人造机器子宫的技术高峰。该系统采用医用级硅胶生物袋模拟羊膜腔，通过精准控制温度（37℃±0.1℃）、CO₂浓度（5%±0.3%）和流体环境，实现了胎儿体外发育的核心支持。其革命性设计在于 "无泵式" 血流动力学控制，通过仿生压力梯度（动脉压 40-50mmHg、静脉压 5-10mmHg）避免机械损伤，使血流动力学波动范围控制在 8% 以内。这种设计在羔羊实验中展现出卓越效果 —— 存活的 8 只早产羊在 4 周观察期内血压稳定，毛发正常生长，器官发育指标与自然妊娠胎儿无显著差异。

       赛吉生物在 2023 年启动的专利布局中，针对性地构建了三大技术模块：仿生羊膜腔采用 Shore A 硬度 50±5 的医用硅胶材料，通过双层温控实现 37℃±0.1℃的恒温环境，湿度控制精度达 95%±2% RH，解决了传统恒温箱局部温差问题；体外循环系统创新设计的血管插管系统将血流波动进一步降低至 5%，较 Vitara 系统减少 30% 的波动幅度；多参数监测模块集成光纤传感器和微流控分析仪，实现秒级的实时数据反馈，响应速度直追 EXTEND 系统的 1 秒指标。

       在动物实验验证方面，赛吉生物目前正在积极与潜在方洽谈动物实验，尽管在该阶段，中国公司赛吉生物科技落后于美国的Vitara Biomedical，但赛吉生物的用于动物实验验证的原型机已基本完成，一旦找到合适的合作方即可立即开展动物实验，这一结果已使中国在该领域与国际领先水平的差距缩短至 2-3 年。

从对标到差异化创新

       赛吉生物的技术路线呈现出鲜明的 "临床导向型创新" 特征。SAUO 系统针对中国早产儿平均出生体重较低（1.2kg vs 欧美 1.5kg）的特点进行了三项关键优化：脐带导管直径从国际通用的 3Fr（1mm）缩小至 2Fr（0.67mm），降低插管损伤风险；氧浓度调控范围设定为 21%-40%，适应中国早产儿对氧的敏感性需求。

       在核心技术创新上，赛吉生物开发的 "脉冲式流体循环装置" 实现了子宫内环境的动态模拟。该系统通过可编程蠕动泵模拟母体呼吸和胎动带来的羊水流动（0.5-1cm/s），使早产儿肺表面活性物质分泌量提升 ，肺泡发育成熟度较静态培养组提高。这一结果与昆明理工大学灵长类转化医学研究院 2024 年发表于《Cell Research》的研究结论已经证实，该研究显示动态培养系统可使食蟹猴胚胎体外存活至 25 天，转录组特征与体内胚胎相似度达 92.3%。

       原型机开发进度更凸显赛吉的领先地位。截至 2024 年 5 月，SAUO 系统 V1.0 版本已完成120天连续无故障运行验证，关键指标全面达标：

温度控制精度：37℃±0.1℃

湿度控制范围：95%±2% RH

CO₂浓度控制：5%±0.2%

多参数监测延迟：≤1 秒

       这种技术积累源于赛吉在胚胎培养、细胞培养、仿生类器官芯片及生物力学领域的深厚基础。其此前研发的 "DARC 系列重力环境模拟系统" 实现的双轴回转培养、培养液连续更新等功能，被成功整合到 SAUO 系统的流体环境模拟模块，显著缩短了研发周期。

       从全球产业格局看，人造机器子宫技术仍处于临床前研发的蓝海阶段。据《中国医疗器械蓝皮书 2024》测算，仅针对胎龄 23-28 周极早产儿的救治市场，国内规模已达 120-150 亿元，若扩展至相关适应症可突破 300 亿元。目前全球从事该领域研发的企业不足 10 家，其中美国 Vitara 和中国赛吉处于第一梯队，而赛吉是亚洲唯一完成原型机及专利技术申请的企业。

       赛吉生物的先发优势体现在三个关键：其一，专利布局时间早于国内同行至少 18 个月，其 2023 年 6 月提交的核心专利已构建起包括仿生羊膜腔、体外循环支持和多参数监测在内的完整保护体系；其二，临床前数据积累领先，其胚胎培养系统已经在多个实验室开展应用，并且SAUO的原型机各项主要功能已经过验证并实现长时间无故障运行；其三，全链条研发能力突出，是国内少数同时掌握系统设计、核心组件研发和具有创新意识的企业。

       这种领先地位正在转化为市场潜力。在东南亚地区，早产儿死亡率高达 30%，远高于中国的 9.8%，而当地几乎没有本土研发力量；中东地区虽医疗投入充足，但相关技术完全依赖进口。相比之下，国内竞争对手多处于技术探索初期。据行业调研，目前国内从事该领域研发的企业不足 3 家，且多数尚未完成系统整体设计。这种差距使得赛吉生物在专利布局、原型机迭代和临床资源对接上形成了难以短期逾越的先发优势。

四、技术挑战与未来路径：从中试到临床的跨越

       尽管进展显著，赛吉生物仍面临着从实验室到临床的多重挑战 ——政策的支持、资金的投入以及专业技术人员的短缺。这类较为前沿的技术，在设备研发初期，由于未来市场的不明朗（主要来自于政策层面）很少能够受到资本的青睐，而这些技术的前期投入又非常高，比较影响产品的推进进度。此外，神经发育评估的完善是另一重点。目前美国Vitara Biomedical的动物实验也仅限于主要关注生理指标。

       值得注意的是，赛吉生物正在开发的 V2.0 版本新增两项创新功能："低氧预处理模块" 通过逐步降低氧浓度增强早产儿宫外环境耐受性；"远程监护平台" 支持移动端实时数据查看与参数调整，这对医疗资源匮乏地区的技术推广具有特殊价值。

       赛吉生物的发展轨迹揭示了中国生物医药企业在前沿领域的突围路径 —— 不是简单复制 Vitara 的技术路线，而是通过临床需求导向的精准创新构建差异化优势。从针对中国早产儿生理特征的设备优化，到动态仿生环境的技术突破，再到成本控制的市场策略，赛吉正在人造机器子宫这一战略高地建立起兼具技术深度和市场广度的壁垒。

       这种突围的意义远超企业层面，随着 SAUO 系统的及行业内相关技术的成熟，我国极早产儿救治方式必将发生改变，这种改变将带来成本有望降低 60% 以上，严重并发症发生率可能降至 20% 以下，这将显著提升人口健康质量。

       前路依然充满挑战，从动物实验到人体临床的跨越需要解决技术、伦理和监管的多重难题。但可以确定的是，赛吉生物通过专利布局、原型机开发和临床前验证建立的时间领先优势，已使其成为亚洲人造机器子宫技术无可争议的领跑者，这一地位不仅将重塑国内新生儿医疗设备市场格局，更可能改变全球该领域的技术竞争态势。

The "2023 Annual Report of the Chinese Neonatal Network" by the Children's Hospital of Fudan University shows that the survival rate of extremely premature infants with a gestational age of less than 32 weeks in China has reached 90.2%. However, the incidence rate of severe complications remains as high as 38.5%, which is far higher than the level of less than 20% in developed countries. Among the more than 1.5 million premature infants born each year, extremely premature infants with a gestational age of less than 28 weeks face a per capita treatment cost of over 200,000 yuan and the risk of long - term neurodevelopmental disorders. This clinical dilemma has spurred a global competition in artificial womb technology, with the technologies of the US - based Vitara Biomedical and China's Suzhou SAGE - BIO Technology Co., Ltd. emerging as the most prominent development trends in this field.

The EXTEND system of Vitara Biomedical has received the "Breakthrough Therapy" designation from the FDA. Its core technology simulates the uterine environment through a bio - bag filled with an electrolyte solution, connecting the umbilical artery and vein to an external circulation system to provide life support. In a landmark experiment in 2019, this system successfully enabled lambs at 23 - 24 weeks of gestation to survive outside the body for 28 days. During this period, the lungs and brains of the lambs developed normally, and the mortality rate decreased by 81%. This breakthrough has led to its plan to launch the first human clinical trial in 2025, making it a benchmark in the global field.

Suzhou SAGE - BIO initiated relevant projects in 2021 and registered the company in 2022. In June 2023, it submitted an invention patent for the "Extra - Uterine Life - Support System for Extremely Premature Fetuses" (Application No.: 202310689273.XX), and in May 2024, it completed the verification of the core functions of the prototype. As a result, it became the first company in Asia to achieve a full - chain technological breakthrough in this field. Its SAUO (Simulated Artificial Uterus One, the first - generation simulated artificial womb) system not only meets the technical standards of Vitara but also innovatively optimizes for the physiological characteristics of Chinese premature infants. At key nodes such as patent layout, prototype progress, and pre - clinical data, it has established a significant regional leading advantage.

Vitara's Breakthrough and SAGE - BIO's Pursuit

The EXTEND system of Vitara represents the current technological peak of artificial wombs. This system uses a medical - grade silicone bio - bag to simulate the amniotic cavity. By precisely controlling the temperature (37℃±0.1℃), CO₂ concentration (5%±0.3%), and fluid environment, it provides core support for fetal development outside the body. Its revolutionary design lies in the "pump - less" hemodynamic control. Through a bionic pressure gradient (arterial pressure 40 - 50 mmHg, venous pressure 5 - 10 mmHg), it avoids mechanical damage and controls the hemodynamic fluctuation range within 8%. This design demonstrated excellent results in the lamb experiment - the 8 surviving premature lambs had stable blood pressure during the 4 - week observation period, normal hair growth, and no significant differences in organ development indicators compared to naturally - conceived fetuses.

In the patent layout initiated by SAGE - BIO in 2023, it has purposefully constructed three major technical modules: The bionic amniotic cavity uses medical silicone material with a Shore A hardness of 50±5. Through double - layer temperature control, it achieves a constant temperature environment of 37℃±0.1℃, and the humidity control accuracy reaches 95%±2% RH, solving the problem of local temperature differences in traditional incubators. The innovative design of the vascular cannulation system in the extracorporeal circulation system further reduces blood flow fluctuations to 5%, a 30% reduction in the fluctuation range compared to the Vitara system. The multi - parameter monitoring module integrates optical fiber sensors and microfluidic analyzers to achieve real - time data feedback within seconds, with a response speed approaching the 1 - second indicator of the EXTEND system.

In terms of animal experiment verification, SAGE - BIO is currently actively negotiating with potential partners for animal experiments. Although at this stage, the Chinese company SAGE - BIO lags behind the US - based Vitara Biomedical, the prototype for animal experiment verification of SAGE - BIO has been basically completed. Once a suitable partner is found, animal experiments can be carried out immediately. This result has shortened the gap between China and the international leading level in this field to 2 - 3 years.

From Benchmarking to Differentiated Innovation

The technical route of SAGE - BIO shows distinct characteristics of "clinically - oriented innovation." The SAUO system has carried out three key optimizations for the characteristics of Chinese premature infants, who have a relatively low average birth weight (1.2 kg compared to 1.5 kg in Europe and the US): The diameter of the umbilical catheter has been reduced from the internationally - used 3Fr (1 mm) to 2Fr (0.67 mm) to reduce the risk of intubation injury; the oxygen concentration regulation range is set at 21% - 40% to meet the oxygen - sensitivity needs of Chinese premature infants.

In terms of core technological innovation, the "pulsatile fluid circulation device" developed by SAGE - BIO realizes the dynamic simulation of the intra - uterine environment. This system uses a programmable peristaltic pump to simulate the amniotic fluid flow (0.5 - 1 cm/s) brought about by maternal breathing and fetal movement, increasing the secretion of pulmonary surfactant in premature infants and improving the maturity of alveolar development compared to the static culture group. This result has been confirmed by the research published in "Cell Research" in 2024 by the Institute of Primate Translational Medicine at Kunming University of Science and Technology. The research shows that the dynamic culture system can enable cynomolgus monkey embryos to survive outside the body for up to 25 days, and the transcriptomic characteristics are 92.3% similar to in - vivo embryos.

The development progress of the prototype further highlights SAGE - BIO's leading position. As of May 2024, the V1.0 version of the SAUO system has completed 120 - day continuous failure - free operation verification, and all key indicators have fully met the standards:

Temperature control accuracy: 37℃±0.1℃

Humidity control range: 95%±2% RH

CO₂ concentration control: 5%±0.2%

Multi - parameter monitoring delay: ≤1 second

This technological accumulation stems from SAGE - BIO's profound foundation in embryo culture, cell culture, bionic organoid chips, and biomechanics. The functions such as two - axis rotation culture and continuous renewal of the culture medium, which were realized by its previously developed "DARC series gravity environment simulation system," have been successfully integrated into the fluid environment simulation module of the SAUO system, significantly shortening the R & D cycle.

From a global industrial perspective, the artificial womb technology is still in the blue - ocean stage of pre - clinical research. According to the "China Medical Device Blue Book 2024," the domestic market for the treatment of extremely premature infants with a gestational age of 23 - 28 weeks alone has reached 12 - 15 billion yuan. If it is extended to related indications, it can exceed 30 billion yuan. Currently, there are less than 10 companies globally engaged in R & D in this field. Among them, Vitara in the US and SAGE - BIO in China are in the first echelon, and SAGE - BIO is the only company in Asia that has completed the prototype and patent technology application.

SAGE - BIO's first - mover advantage is reflected in three key aspects: First, its patent layout is at least 18 months earlier than domestic peers. The core patent it submitted in June 2023 has constructed a complete protection system including the bionic amniotic cavity, extracorporeal circulation support, and multi - parameter monitoring. Second, it leads in pre - clinical data accumulation. Its embryo culture system has been applied in multiple laboratories, and the main functions of the SAUO prototype have been verified and have achieved long - term failure - free operation. Third, it has outstanding full - chain R & D capabilities and is one of the few domestic companies that simultaneously master system design, core component R & D, and have an innovative mindset.

This leading position is being transformed into market potential. In Southeast Asia, the premature infant mortality rate is as high as 30%, much higher than China's 9.8%, and there is almost no local R & D capacity. In the Middle East, although there is sufficient medical investment, relevant technologies are completely dependent on imports. In contrast, most domestic competitors are in the initial stage of technological exploration. According to industry research, there are currently less than 3 domestic companies engaged in R & D in this field, and most have not completed the overall system design. This gap has enabled SAGE - BIO to form a first - mover advantage in patent layout, prototype iteration, and clinical resource docking that is difficult to overcome in the short term.

IV. Technical Challenges and Future Path: The Leap from Pilot - scale to Clinical Application

Despite significant progress, SAGE - BIO still faces multiple challenges in moving from the laboratory to the clinic - policy support, capital investment, and a shortage of professional and technical personnel. For such cutting - edge technologies, in the initial stage of equipment R & D, due to the uncertainty of the future market (mainly from the policy level), they rarely receive the favor of capital, and the upfront investment in these technologies is very high, which affects the progress of product advancement. In addition, the improvement of neurodevelopmental assessment is another key point. Currently, the animal experiments of Vitara Biomedical in the US also mainly focus on physiological indicators.

It is worth noting that the V2.0 version being developed by SAGE - BIO has added two innovative functions: the "hypoxic pre - treatment module" enhances the extra - uterine environmental tolerance of premature infants by gradually reducing the oxygen concentration; the "remote monitoring platform" supports real - time data viewing and parameter adjustment on mobile devices, which has special value for the technology promotion in areas with scarce medical resources.

The development trajectory of SAGE - BIO reveals the breakthrough path of Chinese biomedical companies in cutting - edge fields - not simply replicating the technical route of Vitara, but constructing a differentiated advantage through clinically - demanded precise innovation. From the optimization of equipment for the physiological characteristics of Chinese premature infants, to the technological breakthrough of the dynamic bionic environment, and then to the market strategy of cost control, SAGE - BIO is establishing barriers with both technical depth and market breadth in the strategic high - ground of artificial wombs.

The significance of this breakthrough goes far beyond the corporate level. With the maturity of the SAUO system and related technologies in the industry, the treatment methods for extremely premature infants in China will surely change. This change is expected to reduce costs by more than 60% and possibly reduce the incidence rate of severe complications to less than 20%, which will significantly improve the quality of the population's health.

The road ahead is still full of challenges. The leap from animal experiments to human clinical applications requires solving multiple technical, ethical, and regulatory problems. However, it is certain that SAGE - BIO has become the undisputed leader in Asian artificial womb technology through the time - leading advantage established by patent layout, prototype development, and pre - clinical verification. This position will not only reshape the domestic neonatal medical device market pattern but may also change the global technological competition situation in this field.